Faculty from The Ohio State University (OSU) are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using cancer center resources to leverage group resources. OSU investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, trans planters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. The goal of this application is to provide the infrastructure to support OSU's participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (NLAPS). We will use the support to make scientific discoveries about tumor biology, find better treatments and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) Investigate new therapeutic agents, and their toxicities in Phase I to 1 clinical trials;2) Evaluate the efficacy nd toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively;3) Develop multi-modal approaches using surgical, immunological, and radio therapeutic measures in optimal combinations;4) Integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols;5) Improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) Understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) Improve the management of cancer related symptoms, and 8) enroll patients on trials.
This grant supports OSUCCC's participation in the NCI's sponsored National Cooperative Clinical Trials Network in order to improve the prevention of cancer, better the treatment, and boost the cure rates of adults with cancer. OSUCCC has one of the largest volume academic cancer centers in the US and is fully engaged in NCTN research with each of the existing NCI supported cooperative groups.
|Choueiri, Toni K; Hessel, Colin; Halabi, Susan et al. (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 94:115-125|
|Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650|
|Phipps, Amanda I; Shi, Qian; Zemla, Tyler J et al. (2018) Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev 27:696-703|
|Bassett, Emily A; Palanichamy, Kamalakannan; Pearson, Mitchell et al. (2018) Calpastatin phosphorylation regulates radiation-induced calpain activity in glioblastoma. Oncotarget 9:14597-14607|
|Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2018) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int 121:534-539|
|Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348|
|Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545|
|Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328|
|Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528|
|Rizzotto, Lara; Lai, Tzung-Huei; Bottoni, Arianna et al. (2018) Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia. Leuk Lymphoma 59:1461-1465|
Showing the most recent 10 out of 122 publications